Search

Author/Creator Wolf, I.

3. Managing adverse effects by dose reduction during routine treatment of locally advanced basal cell carcinoma with the hedgehog inhibitor vismodegib: a single centre experience. (17th December 2018)

Authors:
Woltsche, N.; Pichler, N.; Wolf, I.; Di Meo, N.; Zalaudek, I.
Journal:
Journal of the European Academy of Dermatology and Venereology
Issue:
Volume 33:Number 4(2019)
Page Start:
e144
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

4. New somatostatin-drug conjugates for effective targeting pancreatic cancer. Issue 13 (30th July 2018)

Authors:
Ragozin, E.; Hesin, A.; Bazylevich, A.; Tuchinsky, H.; Bovina, A.; Shekhter Zahavi, T.; Oron-Herman, M.; Kostenich, G.; Firer, M.A.; Rubinek, T.; Wolf, I.; Luboshits, G.; Sherman, M.Y.; Gellerman, G.
Journal:
Bioorganic & medicinal chemistry
Issue:
Volume 26:Issue 13(2018)
Page Start:
3825
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

5. Number of evaluated lymph nodes and positive lymph nodes, lymph node ratio, and log odds evaluation in early-stage pancreatic ductal adenocarcinoma: numerology or valid indicators of patient outcome?. Issue 1 (December 2016)

Authors:
Lahat, G.; Lubezky, N.; Gerstenhaber, F.; Nizri, E.; Gysi, M.; Rozenek, M.; Goichman, Y.; Nachmany, I.; Nakache, R.; Wolf, I.; Klausner, J.
Journal:
World journal of surgical oncology
Issue:
Volume 14:Issue 1(2016)
Page Start:
1
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗